Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma
RNA-seq (gene expression) · human · 23 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 23 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcomaCancer immunology, immunotherapy : CII · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE285944_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1207028 and SRA study SRP555524. Searching any of these in the dataset finder brings you back here.
The grouping that defines any comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Sample titles run L6085 … L5042 and carry no group information.
- GSM8713695 L6085
- GSM8713696 L7285
- GSM8713697 L7293
- GSM8713698 L7295
- GSM8713699 L7297
- GSM8713700 L7312
- GSM8713701 L7287
- GSM8713702 L7298
- GSM8713703 L7299
- GSM8713704 L7300
- GSM8713705 L7310
- GSM8713706 L4903
- GSM8713707 L7283
- GSM8713708 L7292
- GSM8713709 L7305
- GSM8713710 L7309
- GSM8713711 L2460
- GSM8713712 L6497
- GSM8713713 L7284
- GSM8713714 L7289
- GSM8713715 L7291
- GSM8713716 L4684
- GSM8713717 L5042
- GSE279213 Targeting De Novo Cholesterol Synthesis as a Therapeutic Strategy in Rhabdomyosarcoma 8 samples same disease briefing · shares therapeutic
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing
- GSE273829 GABA promotes resistance to immunotherapy of patients with TLS-positive tumors [RNA-seq] 92 samples same disease briefing
- GSE300974 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [RNA-seq] 30 samples same disease briefing
- GSE314949 RNA Seq of rhabdomyosarcoma cells with sgRNA targeting oncofusion interacting proteins 30 samples same disease briefing
- GSE279954 mRNA/sRNA Co-Sequencing Reveals Multiple New Targeted Therapy Candidates in Rhabdomyosarcoma 26 samples same disease briefing
- GSE292872 FANCM is Required for the PAX3::FOXO1-Driven Oncogenic Program in Rhabdomyosarcoma [RNA-Seq] 21 samples same disease briefing
- GSE144190 Systematic profiling of synovial sarcoma transcriptome 20 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.